Jessica Galloway-Peña, Ph.D., fellow in the Department of Infectious Diseases, Infection Control and Employee Health at The University of Texas MD Anderson Cancer Center and her colleagues have shown that disruption of the microbiome by illness or the administration of therapeutics can often lead to detrimental effects in immunocompromised cancer patients. Listen to her discuss how a patient’s microbial diversity, even before they start cancer treatment, can be linked to risk of infection during induction chemotherapy.
){kind=link}
Comments